Azura Ophthalmics Receives $16 Million in Series B Funding to Develop Treatment for Leading Cause of Dry Eye Disease
Press Release — Charles Bosworth from Allergan named as Chief Medical Officer to drive clinical strategy — TEL AVIV, Israel–Azura Ophthalmics Ltd. (Azura), a clinical-stage biotechnology company developing innovative therapies for meibomian gland dysfunction (MGD), today announced it has completed a $16 million Series B funding round led by a syndicate of OrbiMed, TPG Biotech […]